home / stock / poai / poai news


POAI News and Press, Predictive Oncology Inc. From 04/20/23

Stock Information

Company Name: Predictive Oncology Inc.
Stock Symbol: POAI
Market: NASDAQ
Website: predictive-oncology.com

Menu

POAI POAI Quote POAI Short POAI News POAI Articles POAI Message Board
Get POAI Alerts

News, Short Squeeze, Breakout and More Instantly...

POAI - Predictive Oncology Announces Reverse Stock Split

Common Stock Will Begin Trading on Split-Adjusted Basis on April 24, 2023 EAGAN, Minn., April 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that it is effecting a reverse stock s...

POAI - InvestorNewsBreaks - Predictive Oncology Inc. (NASDAQ: POAI) Special Meeting of Stockholders Rescheduled after 'Lack of Required Quorum'

Predictive Oncology (NASDAQ: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, h...

POAI - Penny Stocks To Buy? 4 Under $1 To Watch Before Next Week

2023-04-14 10:38:00 ET Thanks to key economic data, this has been one of the wildest weeks in the stock market. Whether you’re trading penny stocks or higher-priced companies, it is almost impossible not to notice all macro catalysts in motion. Whether it was March CPI inflation ...

POAI - InvestorNewsBreaks - Predictive Oncology Inc. (NASDAQ: POAI) Names Oncology Translational Research Leader to Scientific Advisory Board

Predictive Oncology (NASDAQ: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, h...

POAI - Predictive Oncology Announces Appointment of Oncology Translational Research Leader Christoph Reinhard, Ph.D., MBA, to its Scientific Advisory Board

EAGAN, Minn., April 04, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA)...

POAI - InvestorNewsBreaks - Predictive Oncology Inc. (NASDAQ: POAI), Integra Therapeutics Collaborate to Advance Gene Therapy

Predictive Oncology (NASDAQ: POAI) , a science-driven company on the leading edge of oncology drug discovery and development, today announced that it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene writing tools to cure diseases. According to ...

POAI - Predictive Oncology Announces Collaboration with Integra Therapeutics to Advance Gene Therapy

EAGAN, Minn., March 30, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a science-driven company on the leading edge of oncology drug discovery and development, today announces it is partnering with Integra Therapeutics, a company focused on engineering the next generation of&#x...

POAI - Predictive Oncology, Inc. (POAI) Q4 2022 Earnings Conference Call Transcript

2023-03-22 19:05:07 ET Predictive Oncology, Inc. (POAI) Q4 2022 Earnings Conference Call March 22, 2023 12:00 PM ET Company Participants Theresa Ferguson - Senior Director of Marketing Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers ...

POAI - InvestorNewsBreaks - Predictive Oncology Inc. (NASDAQ: POAI) Collaborates to Leverage AI for New Cancer Drugs, Announces 2022 Results

Predictive Oncology’s (NASDAQ: POAI) chief business officer Pamela Bush and Dom Pollard, business development manager at Cancer Research Horizons, joined Proactive’s Natalie Stoberman to discuss their partnership for new cancer drug development. According to the announcement, ...

POAI - Predictive Oncology GAAP EPS of -$0.35, revenue of $1.51M

2023-03-21 17:26:45 ET Predictive Oncology press release ( NASDAQ: POAI ): FY  GAAP EPS of -$0.35. Revenue of $1.51M (+6.3% Y/Y). For further details see: Predictive Oncology GAAP EPS of -$0.35, revenue of $1.51M

Previous 10 Next 10